Patents by Inventor Alejandro Carlos Antalich Raibar

Alejandro Carlos Antalich Raibar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENCAPSULATED MICROPARTICLES AND NANOPARTICLES OF DIMETHYLTRIPTAMINES
    Publication number: 20240408063
    Abstract: The present invention relates to a process of obtaining encapsulated microparticles and/or nanoparticles of DMT/5-MeO-DMT, or pharmaceutically acceptable salts or derivatives thereof and a composition prepared by the process. Pharmaceutical compositions comprising the particles can further include an inhibitor of the Monoamine oxidase (MAOI), and are useful for the personalized treatment of neurological and/or psychiatric disorders, and/or inflammatory disorders.
    Type: Application
    Filed: September 29, 2022
    Publication date: December 12, 2024
    Applicant: Biomind Labs Inc.
    Inventor: Alejandro Carlos ANTALICH RAIBAR
  • PHARMACEUTICAL FORMULATION CONTAINING A PSYCHEDELIC SUBSTANCE OBTAINED BY SELECTIVE LASER SINTERING (SLS) 3D PRINTING
    Publication number: 20230097076
    Abstract: The present invention discloses solid oromucosal pharmaceutical formulations containing a psychedelic selected from psilocybin, psilocin, or mescaline and/or an analog thereof as an active ingredient, a method of preparation of the pharmaceutical form by Selective Laser Sintering (SLS) 3D printing, and treatment of neurological and/or psychiatric disorders, as well as inflammatory disorders.
    Type: Application
    Filed: September 29, 2022
    Publication date: March 30, 2023
    Applicant: Biomind Labs UK Limited
    Inventor: Alejandro Carlos Antalich Raibar
  • DIMETHYLTRIPTAMINE-BASED NASAL SPRAY FOR THE PERSONALISED TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20230094051
    Abstract: The present invention relates to a nasal spray with mucoadhesive properties that gels in situ containing the psychedelic tryptamines DMT or 5-MeO-DMT or pharmaceutically acceptable salts or derivatives thereof, which can be used for personalized treatment of neurological and psychiatric disorders.
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Applicant: Biomind Labs UK Limited
    Inventor: Alejandro Carlos Antalich Raibar